Elanco

Animal Parasiticides Market is Anticipated to Reach USD 15.6 billion, at a CAGR of 5.7% CAGR by 2031 - Report by Transparency Market Research Inc.

Retrieved on: 
Tuesday, December 12, 2023
Merck & Co., Research, Safety, Pig, Urbanization, Boehringer Ingelheim, Bayer, Virbac, Research report, Animal, Parasitism, Merck, Zoonosis, Probiotic, Nanotechnology, Growth, Knowledge, Livestock, Poultry, Cattle, Pet industry, Agriculture, Fine chemical, Elanco

WILMINGTON, Del., Dec. 12, 2023 /PRNewswire/ -- The global animal parasiticides market is estimated to flourish at a CAGR of 5.7% from 2023 to 2031. According to Transparency Market Research, sales of animal parasiticides are slated to total US$ 15.6 billion by the end of the aforementioned period of assessment.

Key Points: 
  • Growing urbanization, rising disposable income, and improved awareness about animal health amplify the demand for effective parasiticides.
  • Spot-on treatments and oral tablets dominate the animal parasiticides market, offering efficient and convenient solutions for parasite control in animals.
  • Food-producing animals, particularly cattle, poultry, and swine, lead the animal parasiticides market due to their extensive agricultural significance.
  • North America leads the animal parasiticides market due to advanced research, stringent regulations, and robust veterinary healthcare infrastructure.

Alveolus Bio Enters Into Strategic Collaboration with BiomEdit

Retrieved on: 
Friday, December 8, 2023
Pet, Research, Disease, Coronavirus, Respiratory disease, Science, Animal, Eli Lilly, Therapy, Alveolus, Partnership, Human, Elanco, Synthetic biology

and BIRMINGHAM, Ala., Dec. 8, 2023 /PRNewswire/ -- Alveolus Bio today announced a strategic scientific collaboration with BiomEdit, an emerging animal health biotechnology company leveraging microbiome science and synthetic biology to develop novel products to prevent and treat disease in animals.

Key Points: 
  • and BIRMINGHAM, Ala., Dec. 8, 2023 /PRNewswire/ -- Alveolus Bio today announced a strategic scientific collaboration with BiomEdit, an emerging animal health biotechnology company leveraging microbiome science and synthetic biology to develop novel products to prevent and treat disease in animals.
  • BiomEdit, founded in 2022, originated through a carveout from Elanco Animal Health, formerly a division of Eli Lilly, in a strategic partnership with Ginkgo Bioworks.
  • Alveolus Bio will be studying BiomEdit's proprietary consortium of commensal strains, which secrete metabolites with documented anti-inflammatory and immune-modulating properties.
  • "This collaboration with BiomEdit shows great potential for fortifying Alveolus' asset pipeline and advancing BiomEdit's bioproduct delivery capabilities," remarked Gaurav Mehta, Chief Executive Officer of Alveolus Bio.

Elanco Animal Health Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, November 7, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, FDA, Research, Sale, Farm Animal, Vaccine, Poultry, Cat, Pressure, EBITDA, Lubabegron, Weight gain, Treasury, Carbon, Article, JAK, Methane, Chronic kidney disease, Lotilaner, North American Pet Health Insurance Association, Anemia, Dog, Tick, Appetite, Video game, Pharmaceutical industry, Elanco, EU

In the third quarter of 2023, the Advantage® Family of products and Seresto® contributed $103 million and $41 million, respectively.

Key Points: 
  • In the third quarter of 2023, the Advantage® Family of products and Seresto® contributed $103 million and $41 million, respectively.
  • Asset impairment, restructuring and other special charges were $16 million in the third quarter of 2023 compared to $26 million in the third quarter of 2022.
  • The reported effective tax rate was 0.2% in the third quarter of 2023, compared to (47.7)% in the third quarter of 2022.
  • Adjusted EBITDA was $214 million in the third quarter of 2023, a 5% increase compared to the third quarter of 2022.

Bexacat™ (bexagliflozin tablets), the First and Only Tablet to Treat Feline Diabetes, Named “Overall Cat Health Product Of The Year” In 2023 Pet Innovation Awards

Retrieved on: 
Thursday, November 2, 2023
Science, FDA, Research, Retail, Veterinarian, NYSE, Innovation, Food, Diabetes, Vomiting, Human, Cat, Weight loss, Diarrhea, Elanco, Service, DM, SGLT2, Argyreia nervosa, Liver, Type 1 diabetes, Pancreatitis, ELAN, Urine, Dehydration, Disease, Risk, Farmer, Lethargy, Depression, Diabetic ketoacidosis, Pet, Diagnosis, Death, Glucose, Coma, Insulin, Pharmaceutical industry, Health, Housing

Bexacat is a once-daily tablet that works to lower blood sugar by increasing urine excretion of glucose through inhibition of sodium-glucose cotransporter 2 (SGLT2).

Key Points: 
  • Bexacat is a once-daily tablet that works to lower blood sugar by increasing urine excretion of glucose through inhibition of sodium-glucose cotransporter 2 (SGLT2).
  • “Bexacat removes some of the traditional challenges associated with treating feline diabetes and is a more efficient option for today’s on-the-go pet owner lifestyle.
  • Bexacat is needle-free and dosed to felines at a minimum weight of 6.6 lbs in order to ensure dosing accuracy.
  • The 2023 Pet Innovation Awards attracted more than 2,000 nominations from around the world.

Athian and Elanco Animal Health Team Up to Transform Food Production through Methane Reduction

Retrieved on: 
Thursday, November 2, 2023
Consumer, Environment, Sustainability, Agriculture, Pets, Natural Resources, Manure, Sale, NYSE, Health, Farm, Poultry, Global warming potential, Livestock, U.S. Department of Agriculture Cotton Annex, Carbon, USDA, Milk, Carbon accounting, Multimedia, Food chain, ELAN, Farmer, U.S. Department of Defense Strategy for Operating in Cyberspace, Renewable energy, Elanco

View the full release here: https://www.businesswire.com/news/home/20231102251225/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231102251225/en/
    Athian is verifying its first farms and creating, certifying and selling carbon credits within the dairy value chain.
  • “As a leader in animal health, we’ve focused first on delivering enteric methane reduction solutions to producers.
  • Athian and Elanco are participating in the Reuters Transform Food USA 2023 event on Thursday, November 2, 2023, to speak more about this transformation.
  • Enteric methane reduction carbon credits are now available for purchase through Athian’s insetting carbon marketplace.

Elanco Confirms Date and Conference Call for Third Quarter 2023 Financial Results Announcement

Retrieved on: 
Tuesday, October 17, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, NYSE, Elanco, ELAN, Pharmaceutical industry, Online shopping, Video game

Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2023 financial results on Tuesday, November 7, 2023.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2023 financial results on Tuesday, November 7, 2023.
  • Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
  • The conference call will begin at 8:00 a.m. eastern time.
  • Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco’s website on our events and presentations page.

Elanco Announces Corporate Governance Enhancements

Retrieved on: 
Wednesday, October 4, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, IPO, Elanco, Article, Securities and Exchange Commission (Philippines), ELAN, Annual general meeting, Security (finance), NYSE, Audit

Elanco Animal Health Incorporated (NYSE: ELAN) announced today that the Board of Directors has commenced a process to amend the Company’s corporate governing documents as part of a comprehensive governance review following the Company’s 2023 Annual Meeting of Shareholders.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) announced today that the Board of Directors has commenced a process to amend the Company’s corporate governing documents as part of a comprehensive governance review following the Company’s 2023 Annual Meeting of Shareholders.
  • “We have engaged with our shareholders, particularly during the past three years, on corporate governance matters,” said R. David Hoover, Chairman of the Board and the Corporate Governance Committee.
  • “Given the solid foundation Elanco has built during the five years since our IPO, we believe now is the time to make these additional governance changes.
  • At Elanco, we are committed to strong corporate governance and will continue to foster open communication with our shareholders.”
    More information regarding the proposals requiring shareholder approval will be included in the Company’s proxy statement to be filed with the Securities and Exchange Commission prior to the 2024 Annual Meeting of Shareholders.

Elanco Launches Varenzin™-CA1 (molidustat oral suspension) – the First-of-its-Kind Oral Treatment for Anemia in Cats with Chronic Kidney Disease

Retrieved on: 
Thursday, September 7, 2023
Health, Consumer, Agriculture, Natural Resources, Pets, Pharmaceutical, Veterinary, Hypersensitivity, Seizure, Acromegaly, Syringe, Disease, FDA Center for Devices and Radiological Health, Somatic symptom disorder, Chronic kidney disease, Hypersalivation, Breeding, Veterinarian, Dehydration, Oxygen, Weight loss, Food and Drug Administration, Bone marrow, Ageing, Quality of life, Nutrient, HCT, Medicine, Appetite, Coronary thrombosis, Vomiting, ELAN, Animal, Euthanasia, Patient, Liver, Lethargy, Anemia, Blood, Pet, PCV, Heart rate, FDA, Veterinary medicine, Death, CKD, Woman, Hematocrit, NYSE, Polycythemia, Food, Cat, Dietary supplement, Medical imaging, Poultry farming, Elanco

CKD is common among mature and senior cats, occurring in about 15-30% of feline patients over 12 years old.

Key Points: 
  • CKD is common among mature and senior cats, occurring in about 15-30% of feline patients over 12 years old.
  • “Chronic kidney disease is not curable, so veterinarians and pet owners are focused on improving quality of life and slowing disease progression in affected cats,” said Dr. Melinda Wood, Specialty Consulting Veterinarian at Elanco.
  • Varenzin-CA1 is indicated for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats.
  • Elura has not been evaluated in cats younger than 5 months of age or in breeding, pregnant or lactating cats.

National Dog Day Returns on Saturday, August 26th to Celebrate Our Canine Companions and Encourage Adoption.

Retrieved on: 
Friday, August 25, 2023
ACT, Human, Elanco, Travel, Crime, Parasitism, Auto Trader, Lungworm, Cigarette Burns, Multimedia, Affection, National Dog Show, Child, Dog, Love, City, LOS, Pet-friendly dormitories, News, Social media, Pharmaceutical industry

LOS ANGELES, Aug. 24, 2023 /PRNewswire-PRWeb/ -- National Dog Day 2023 is set to ignite the online world and airwaves with an abundance of captivating photos and videos featuring adorable dogs from all walks of life and especially from rescues and shelters. Too many of these furry souls find themselves confined to kennels, yearning for companionship, their hearts beating with the fervent hope that their endearing eyes will weave an unbreakable spell of affection. They eagerly await liberation from the grip of abandonment, longing for the embrace of a new and loving pet parent.

Key Points: 
  • They eagerly await liberation from the grip of abandonment, longing for the embrace of a new and loving pet parent.
  • National Dog Day, through the power of social media, will prove instrumental in connecting these dogs with loving families.
  • Originally launched and celebrated in the United States, National Dog Day is now celebrated worldwide.
  • This year marks the 19th anniversary of National/International Dog Day and millions of dogs finding new homes.

TheracosBio Announces Royalty Financing Agreement with HealthCare Royalty

Retrieved on: 
Tuesday, August 22, 2023
Science, Veterinary, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Elanco, Patient, SGLT2, Pharmaceutical industry, Bexagliflozin

TheracosBio today announced that its consolidated group of companies has signed a royalty financing agreement with HealthCare Royalty (HCRx).

Key Points: 
  • TheracosBio today announced that its consolidated group of companies has signed a royalty financing agreement with HealthCare Royalty (HCRx).
  • Under the terms of the agreement, HCRx will be entitled to a portion of the future royalties and milestone payments from the commercialization of a veterinary product developed by TheracosBio and commercialized by Elanco Animal Health.
  • Last month, TheracosBio announced the commercial launch of Brenzavvy™ (bexagliflozin), its FDA-approved SGLT2 inhibitor.
  • “This financing is a tremendous asset for TheracosBio at a pivotal time for the company,” said Brian Connelly, President and CEO of TheracosBio.